Santen Pharmaceutical Co., Ltd. (SNPHY)
11.78
0.00 (0.00%)
USD |
OTCM |
Aug 25, 16:00
Santen Pharmaceutical Enterprise Value : 3.485B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 3.485B |
| August 24, 2026 | 3.487B |
| August 21, 2026 | 3.509B |
| August 20, 2026 | 3.685B |
| August 19, 2026 | 3.535B |
| August 18, 2026 | 3.578B |
| August 17, 2026 | 3.689B |
| August 14, 2026 | 3.567B |
| August 13, 2026 | 3.614B |
| August 12, 2026 | 3.673B |
| August 11, 2026 | 3.691B |
| August 10, 2026 | 3.650B |
| August 07, 2026 | 3.484B |
| August 06, 2026 | 3.747B |
| August 05, 2026 | 3.628B |
| August 04, 2026 | 3.443B |
| August 03, 2026 | 3.362B |
| July 31, 2026 | 3.501B |
| July 30, 2026 | 3.496B |
| July 29, 2026 | 3.529B |
| July 28, 2026 | 3.546B |
| July 27, 2026 | 3.557B |
| July 24, 2026 | 3.445B |
| July 23, 2026 | 3.437B |
| July 22, 2026 | 3.773B |
| Date | Value |
|---|---|
| July 21, 2026 | 3.545B |
| July 20, 2026 | 3.853B |
| July 17, 2026 | 3.898B |
| July 16, 2026 | 3.839B |
| July 15, 2026 | 3.869B |
| July 14, 2026 | 3.916B |
| July 13, 2026 | 4.136B |
| July 10, 2026 | 4.023B |
| July 09, 2026 | 4.164B |
| July 08, 2026 | 3.991B |
| July 07, 2026 | 4.128B |
| July 06, 2026 | 4.168B |
| July 02, 2026 | 4.034B |
| July 01, 2026 | 4.081B |
| June 30, 2026 | 4.022B |
| June 29, 2026 | 3.960B |
| June 26, 2026 | 3.809B |
| June 25, 2026 | 3.918B |
| June 24, 2026 | 3.680B |
| June 23, 2026 | 3.664B |
| June 22, 2026 | 3.614B |
| June 18, 2026 | 3.491B |
| June 17, 2026 | 3.628B |
| June 16, 2026 | 3.538B |
| June 15, 2026 | 3.500B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 85.56B |
| Daiichi Sankyo Co., Ltd. | 31.72B |
| Eisai Co., Ltd. | 8.547B |
| Chugai Pharmaceutical Co., Ltd. | 66.09B |
| Ono Pharmaceutical Co., Ltd. | 6.600B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 45.18M |
| Revenue (Quarterly) | 432.73M |
| Total Expenses (Quarterly) | 387.58M |
| EPS Diluted (Quarterly) | 0.1399 |
| Gross Profit Margin (Quarterly) | 54.66% |
| Profit Margin (Quarterly) | 10.44% |
| Earnings Yield | 6.52% |
| Operating Earnings Yield | 7.62% |